- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Journal Introduction
- Editorial Board
- Youth Editorial Board
- Editorial Board Charter
- Subscriptions
- Archive
- Current Issue
- Past Issues
- Priority Publication
- Virtual Collection
- Recommended Articles
- Submission
- Submission Process
- Submission Guidelines
- Download
- Contact us
- For Reviewers
- Guidelines for Reviewers
- Peer Reviewed Policies
- Statement and Policies
- Ethics and Malpractice
- Research Ethics Policies
- Repetition Detection
- Corrections and Retractions
- Editorial Policies
- Open Access Statement
- Website Responsibility
Safety evaluation of sintilimab in combination with chemotherapy for the treatment of cholangiocarcinoma
- ZHONGGUO YAOFANG Vol. 36, Issue 4, Pages: 482-485(2025)
- 作者机构：
1.中山大学附属第三医院药学部，广州 510630
2.中山大学附属第三 医院大数据人工智能中心，广州 510630
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2025.04.16
CLC： R969.3;R979.1;R735.8Received：14 August 2024，
Revised：2025-01-23，
Accepted：24 January 2025，
Published：28 February 2025
- 稿件说明：
移动端阅览
钟豪,林航,卢娅欣,等.信迪利单抗联合化疗用于胆管癌的安全性评价[J].中国药房,2025,36(04):482-485.
ZHONG Hao,LIN Hang,LU Yaxin,et al.Safety evaluation of sintilimab in combination with chemotherapy for the treatment of cholangiocarcinoma[J].ZHONGGUO YAOFANG,2025,36(04):482-485.
钟豪,林航,卢娅欣,等.信迪利单抗联合化疗用于胆管癌的安全性评价[J].中国药房,2025,36(04):482-485. DOI： 10.6039/j.issn.1001-0408.2025.04.16.
ZHONG Hao,LIN Hang,LU Yaxin,et al.Safety evaluation of sintilimab in combination with chemotherapy for the treatment of cholangiocarcinoma[J].ZHONGGUO YAOFANG,2025,36(04):482-485. DOI： 10.6039/j.issn.1001-0408.2025.04.16.
摘要
目的
2
评价信迪利单抗联合化疗用于胆管癌的安全性。
方法
2
收集2021年1月1日－2022年12月31日于我院化疗的胆管癌患者资料，根据用药方案的不同分为对照组（29例）和观察组（18例）。对照组患者予以注射用盐酸吉西他滨+注射用顺铂或注射用奥沙利铂，观察组患者在此基础上加用信迪利单抗注射液。两组患者于每个治疗周期开始前及结束后均检查血常规、肝肾功能、生化指标等，并观察不良反应发生情况。采用Naranjo’s评估量表评价不良反应与使用药物的相关性。
结果
2
血液毒性反应与两组使用药物的相关性均为“很可能”，但观察组的评分更高、相关性更强；肝毒性反应与对照组使用药物的相关性为“可疑”，与观察组使用药物的相关性为“很可能”；胃肠道症状与两组使用药物的相关性均为“有可能”；全身症状、皮肤毒性、肌肉骨骼毒性、内分泌毒性、肾毒性的相关性均为“可疑”。观察组患者血液毒性总发生率显著高于对照组（
P
＝0.014）。两组患者的肝毒性、胃肠道症状、全身症状、皮肤毒性、肌肉骨骼毒性、内分泌毒性及肾毒性的总发生率以及≥3级血液毒性、肝毒性发生率比较，差异均无统计学意义（
P
＞0.05）。发生不良反应的患者经停药或对症支持治疗后，症状均有所缓解。治疗期间未有患者死亡。
结论
2
信迪利单抗联合化疗可能会增加胆管癌患者血液毒性反应的发生风险，尤其是血小板减少，但不良反应在可控范围内，总体安全性良好。
Abstract
OBJECTIVE
2
To assess the safety profile of sintilimab in combination with chemotherapy for the treatment of cholangiocarcinoma.
METHODS
2
The data of patients with cholangiocarcinoma from January 1st， 2021 to December 31st， 2022 were collected and divided into control group （29 cases） and observation group （18 cases） based on different medication regimens. Patients in the control group were treated with Gemcitabine hydrochloride for injection+Cisplatin for injection or Oxaliplatin for injection， the observation group was treated with Sintilimab injection based on the control group. Patients in each group underwent blood routine， liver and kidney function， biochemical and other examinations before and after each treatment cycle to observe the occurrence of adverse drug reactions. The correlation of adverse drug reactions with drugs was evaluated with Naranjo’s scale.
RESULTS
2
The correlation between blood toxicity and drug use was deemed “probable” in both groups； however， the observation group exhibited a significantly higher score， indicating a stronger correlation. In the control group， hepatotoxic reactions were classified as “suspicious” whereas in the observation group， they were categorized as “probable”. The correlation of gastrointestinal symptoms between the two groups was considered “possible”. Systemic symptoms， skin toxicity， musculoskeletal toxicity， endocrine toxicity and renal toxicity were all classified as having a “suspicious” correlation with drug use. The total incidence of blood toxicity in the observation group was significantly higher than control group （
P
＝0.014）. There was no statistically significant difference in the total incidences of hepatotoxic， gastrointestinal symptoms， systemic symptoms， skin toxicity， musculoskeletal toxicity， endocrine toxicity， renal toxicity， or the incidence of grade 3 or higher blood toxicity， hepatotoxic between the two groups （
P
＞0.05）. For the patients experiencing adverse drug reactions， the symptoms were alleviated following drug discontinuatio
n or symptomatic supportive treatment. No fatalities occurred during the treatment period.
CONCLUSIONS
2
Sintilimab combined with chemotherapy may significantly increase the risk of blood toxicity in patients with cholangiocarcinoma， especially thrombocytopenia， but the adverse reactions are within a controllable range， and the overall safety is good.
关键词
Keywords
references
朱丹 ， 李月阳 ， 宋燕青 ， 等 . PD-1抑制剂信迪利单抗的临床研究进展 [J ] . 中国医院药学杂志 ， 2020 ， 40 （ 1 ）： 120 - 123 .
ZHU D ， LI Y Y ， SONG Y Q ， et al . The clinical research progress of PD-1 inhibitor：sintilimab [J ] . Chin J Hosp Pharm ， 2020 ， 40 （ 1 ）： 120 - 123 .
夏铮铮 ， 张见雨 ， 曲爽 ， 等 . 某肿瘤医院信迪利单抗超适应证用药循证评价 [J ] . 今日药学 ， 2023 ， 33 （ 5 ）： 352 - 355 .
XIA Z Z ， ZHANG J Y ， QU S ， et al . Evidence-based evaluation of off-label use of sintilimab in a cancer hospital [J ] . Pharm Today ， 2023 ， 33 （ 5 ）： 352 - 355 .
KHAN S A ， TAVOLARI S ， BRANDI G . Cholangiocarcinoma：epidemiology and risk factors [J ] . Liver Int ， 2019 ， 39 （ Suppl. 1 ）： 19 - 31 .
BANALES J M ， MARIN J J G ， LAMARCA A ， et al . Cholangiocarcinoma 2020：the next horizon in mechanisms and management [J ] . Nat Rev Gastroenterol Hepatol ， 2020 ， 17 （ 9 ）： 557 - 588 .
VALLE J W ， FURUSE J ， JITLAL M ， et al . Cisplatin and gemcitabine for advanced biliary tract cancer：a meta-analysis of two randomised trials [J ] . Ann Oncol ， 2014 ， 25 （ 2 ）： 391 - 398 .
RIMINI M ， FORNARO L ， LONARDI S ， et al . Durva-lumab plus gemcitabine and cisplatin in advanced biliary tract cancer：an early exploratory analysis of real-world data [J ] . Liver Int ， 2023 ， 43 （ 8 ）： 1803 - 1812 .
OH D Y ， LEE K H ， LEE D W ， et al . Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer：an open-label，single-centre，phase 2 study [J ] . Lancet Gastroenterol Hepatol ， 2022 ， 7 （ 6 ）： 522 - 532 .
OH D Y ， HE A R ， QIN S K ， et al . Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer [J ] . NEJM Evid ， 2022 ， 1 （ 8 ）： EVIDoa2200015 .
SHI G M ， HUANG X Y ， WU D ， et al . Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cho-langiocarcinoma：a single-center，single-arm，phase 2 study [J ] . Signal Transduct Target Ther ， 2023 ， 8 （ 1 ）： 106 .
KELLEY R K ， UENO M ， YOO C ， et al . Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer（KEYNOTE-966）：a randomised，double-blind，placebo-controlled，phase 3 trial [J ] . Lancet ， 2023 ， 401 （ 10391 ）： 1853 - 1865 .
DING X Y ， LI G X ， SUN W ， et al . Sintilimab combined with lenvatinib for advanced intrahepatic cholangiocarcinoma in second-line setting：a multi-center observational study [J ] . Front Oncol ， 2022 ， 12 ： 907055 .
JIN S L ， ZHAO R H ， ZHOU C ， et al . Feasibility and tole-rability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers：an open-label，single-arm，phase Ⅱ clinical trial [J ] . Int J Cancer ， 2023 ， 152 （ 8 ）： 1648 - 1658 .
王忠辉 ， 陈国林 ， 苏树英 . 安罗替尼联合信迪利单抗治疗复发性胆管癌1例 [J ] . 岭南现代临床外科 ， 2022 ， 22 （ 6 ）： 582 - 587 .
WANG Z H ， CHEN G L ， SU S Y . Effective treatment of recurrent cholangiocarcinoma with arotinib combined with sintilimab injection：a case report and literature review [J ] . Lingnan Mod Clin Surg ， 2022 ， 22 （ 6 ）： 582 - 587 .
LIU J ， WANG C Y ， CAO L ， et al . Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules（S-1）：a case report [J ] . Ann Palliat Med ， 2020 ， 9 （ 2 ）： 497 - 503 .
ZHANG J J ， WU L H ， LIU J ， et al . A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor：a case report and literature review [J ] . Immunotherapy ， 2020 ， 12 （ 8 ）： 555 - 561 .
中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）胆道恶性肿瘤诊疗指南2021 [M ] . 北京 ： 人民卫生出版社 ， 2021 ： 119 - 137 .
Chinese Society of Clinical Oncology Guidelines Working Committee . Chinese Society of Clinical Oncology（CSCO）diagnosis and treatment guidelines for biliary malignancy 2021 [M ] . Beijing ： People’s Medical Publishing House ， 2021 ： 119 - 137 .
陈静静 ， 钱佩佩 ， 曹凯 ， 等 . 我国药品不良反应关联性评价方法与诺氏评估量表法的对比与分析 [J ] . 中国药事 ， 2020 ， 34 （ 8 ）： 988 - 992 .
CHEN J J ， QIAN P P ， CAO K ， et al . Comparison and analysis of causality assessment method in China and Naranjo’s method in the evaluation of adverse drug reactions [J ] . Chin Pharm Aff ， 2020 ， 34 （ 8 ）： 988 - 992 .
National Cancer Institute . Common terminology criteria for adverse events （CTCAE） version 5.0 .[EB/OL ] . [ 2023-11-27 ] . https：//ctep.cancer.gov/protocoldevelopment/ electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf .
YOST K E ， SATPATHY A T ， WELLS D K ， et al . Clonal replacement of tumor-specific T cells following PD-1 blockade [J ] . Nat Med ， 2019 ， 25 （ 8 ）： 1251 - 1259 .
杜成 ， 金山琇 ， 谢晓冬 . 从微观到宏观漫谈肿瘤免疫检查点抑制剂疗效的影响因素 [J ] . 中国癌症防治杂志 ， 2021 ， 13 （ 6 ）： 575 - 584 .
DU C ， JIN S X ， XIE X D . A discussion of the influencing factors of the efficacy of tumor immune checkpoint inhibitors：from the micro to the macro [J ] . Chin J Oncol Prev Treat ， 2021 ， 13 （ 6 ）： 575 - 584 .
0
Views
67
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.